Edwards Lifesciences reported that its core transcatheter aortic valve replacement (TAVR) business grew volume by 15% year-over-year in Q4, driven by market share gains in Europe and Asia. The company also highlighted a 20% increase in transcatheter mitral and tricuspid therapies (TMTT) procedures as clinicians adopt its next-generation repair and replacement platforms. Installed base expanded by over 300 new treatment centers globally, underpinning a durable revenue runway for 2026 and beyond.

Despite robust procedural growth, Edwards faces near-term challenges from slowing procedure volume growth in select developed markets and a 3% FX translation headwind on reported revenue. Rising interest rates have constrained hospital capital budgets, leading to delays in high-value capital equipment sales. Management expects operating margin to compress by 100 to 150 basis points in fiscal 2026 as it absorbs these pressures and invests in field infrastructure to support expanding treatment volumes.

Analysts forecast mid-single-digit revenue growth for the full year, with free cash flow conversion targeted at 85%. Edwards ended Q4 with $1.2 billion in net cash after completing a $600 million share repurchase program in October. The company reiterated its long-term margin target of 28–30% and plans to reinvest 200 basis points of margin expansion into R&D for next-generation TMTT devices. While near-term dilution is expected from FX and capital spending, the equity remains positioned for accretion as global adoption of transcatheter therapies accelerates.